Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 1.00 |
| ▸ | CASR | P41180 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 4/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26804101 | 0.88 | SLC6A3 (0.78) | SLC6A3CASRFOLH1KMT2A | |
| SCHEMBL26804107 | 0.84 | SLC6A3 (0.82) | SLC6A3CASRFOLH1RAB9A | |
| SCHEMBL26804115 | 0.84 | SLC6A3 (0.82) | SLC6A3CASRRAB9AKMT2AMAPT | |
| SCHEMBL26804129 | 0.83 | SLC6A3 (0.71) | SLC6A3CNR1FOLH1POLBKMT2A | |
| SCHEMBL23902831 | 0.82 | SLC6A3 (1.00) | SLC6A3CASR | |
| SCHEMBL26804134 | 0.81 | SLC6A3 (0.78) | SLC6A3CASRFOLH1KMT2AMAPT | |
| SCHEMBL26804098 | 0.81 | SLC6A3 (0.85) | SLC6A3CASRFOLH1KMT2A | |
| SCHEMBL26804142 | 0.81 | SLC6A3 (0.67) | SLC6A3CASRFOLH1 | |
| SCHEMBL11048686 | 0.79 | CNR1 (0.70) | SLC6A3CASRCNR1RAB9A | |
| SCHEMBL26804104 | 0.79 | SLC6A3 (0.74) | SLC6A3CASRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | UNIV TEXAS TECH SYSTEM (US) | 2025-05-15 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-11225459-B2 | Substituted bisphenylalkylurea compounds and methods | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225459-B2 | Substituted bisphenylalkylurea compounds and methods | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200181069-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181069-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2020033909-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TP53, ULK1, TFEB | SLC6A3 1928/4885CASR 4381/4885CNR1 3119/4885 |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | SLC6A3 1928/4885CASR 4381/4885CNR1 3119/4885 |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | SLC6A3 2908/4885CASR 4362/4885CNR1 2694/4885 |
| US-11225459-B2 | Substituted bisphenylalkylurea compounds and methods | HTR3B, HTR3A, HTR3C | SLC6A3 4/4885CASR 941/4885CNR1 78/4885 |
| US-20200181069-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS | HTR3B, HTR3A, HTR3C | SLC6A3 4/4885CASR 941/4885CNR1 78/4885 |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | SLC6A3 1928/4885CASR 4381/4885CNR1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.